An iPSC manufacturing strategy for cell therapies drops the cost of goods sold to about $5,000 per dose, down from $115,000 per dose for autologous therapeutics and $40,000 per dose for allogeneic ...
DUBLIN--(BUSINESS WIRE)--The "Induced Pluripotent Stem Cell (iPSC) Industry Report - Market Size, Trends, & Forecasts, 2025" report has been added to ResearchAndMarkets.com's offering. Since the ...
ORLANDO, Fla.--(BUSINESS WIRE)--Hesperos, a leader in recreating human biology with its’ Human-on-a-Chip ® platform, has announced a breakthrough development of a human induced pluripotent stem cell ...
This article is based on a poster originally authored by Malika Bsibsi, A. Popalzij, Matteo Zanella, Lieke Geerts, Mark Musters, Inês Ferreira, Stefan Kostense, David F. Fischer and Marijn Vlaming, ...
In this interview, we speak to Keith Olson and Coby Carlson from FUJIFILM Cellular Dynamics about their iPSC technology and how it is making breakthroughs in blood-brain barrier research. Please can ...
The blood-brain barrier protects the central nervous system by tightly regulating what crosses between the two compartments. Neurons are vulnerable if the barrier suffers damage or weakens with age, ...
Making therapies from induced pluripotent stem cells (iPSCs) usually takes many experiments to scale up production. Wei Xie, PhD, assistant professor of mechanical and industrial engineering at ...
The MarketWatch News Department was not involved in the creation of this content. Phenocell and Amarna Therapeutics Awarded Eurostars Grant to Assess a Gene Therapy for Dry AMD using a novel ...
The term cerebral small vessel disease (SVD) refers to the sum of all pathological processes affecting the small vessels of the brain. Although SVD has been recognized as a leading cause of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results